Expanded PBS listing for empagliflozin An RACGP expert describes the change as a ‘double win’, with the 1 April expansion to benefit more patients with type 2 diabetes.
Drug expanded on PBS for CKD treatment GPs can now prescribe empagliflozin for eligible patients with chronic kidney disease, but should be aware of specific eligibility criteria.
GLP-1 RA prescribing checks flagged GPs may soon need Services Australia approval prior to prescribing the diabetes medications, following evidence of ‘high use’ outside of PBS restrictions.
SGLT2 inhibitors for kidney and heart disease Normally used as a glucose-lowering agent in the treatment of type 2 diabetes, SGLT2 inhibitors have been found to have beneficial effects in patients with heart failure and kidney disease.
Can PPIs impact lung cancer treatment? New research suggests a common medication used by up to 30% of cancer patients may adversely affect immune therapy treatment.
ACE-inhibitors, ARBs and COVID-19: What GPs need to know Some are considering the role of antihypertensives in the coronavirus pandemic, but experts warn against abruptly stopping these medications.
Popular hypertension drug linked with suicide Angiotensin receptor blockers may be associated with a higher risk of suicide than alternative medications, a new study has found.
Evidence of PPI danger grows Extended use of common heartburn medication has been linked to potentially fatal cardiovascular disease, stomach cancer and chronic kidney disease.